{"analyses":[{"ciLowerLimit":"0.469","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.665","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","pValueComment":"All analyses based on final DBL were descriptive only with p-values reported as nominal.","paramType":"Hazard Ratio (HR)","paramValue":"0.559","statisticalMethod":"Stratified log-rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.6","upperLimit":"8.3","value":"6.3"},{"groupId":"OG001","lowerLimit":"4.3","upperLimit":"6.0","value":"5.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"357"},{"groupId":"OG001","value":"355"}],"units":"Participants"}],"description":"PFS as assessed by blinded IRC per RECIST 1.1 was defined as the time from randomization to the date of the first documented tumor progression, or death due to any cause, whichever occurred earlier.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received cemiplimab monotherapy","id":"OG000","title":"Cemiplimab"},{"description":"Participants received platinum-based doublet chemotherapy","id":"OG001","title":"Chemotherapy"}],"paramType":"MEDIAN","populationDescription":"FAS included all randomized participants.","reportingStatus":"POSTED","timeFrame":"Up to 94 months","title":"Progression-free Survival (PFS) Per Blinded IRC","type":"PRIMARY","unitOfMeasure":"months"}